Selected Publications

A. DeMichele A.S. Clark L. Bayne K. Rohn I. Nivar P. Wileyto L. Berry S. DeLuca J. Savage I. Makhlin T.C. Pan J. Graves G. Belka J. Wang N. Shih D. Berry A. Nayak M. Feldman L. Chodosh: 244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”). ESMO Abstract. Annals of Oncology, 34: S281, October 2023 Notes: Abstract at ESMO 2023 - Was presented as a mini-oral by Dr. DeMichele

Fradley MG, Nguyen NHK, Madnick D, Chen Y, DeMichele A, Makhlin I, Dent S, Lefebvre B, Carver J, Upshaw JN, DeRemer D, Ky B, Guha A, Gong Y.: Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer. J Am Heart Assoc 12: e029361, Jun 2023.

Chen S, Paul MR, Sterner CJ, Belka GK, Wang D, Xu P, Sreekumar A, Pan TC, Pant DK, Makhlin I, DeMichele A, Mesaros C, Chodosh LA.: PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies. Breast Cancer Res 25(1): 1, Jan 3 2023.

Kaufmann T, Chang P, Rosenberg SM, Frank E, Hobbs B, Bayne LJ, Nivar I, Goodspeed BL, Rohn KM, Kugler EM, Fox K, Domchek SM, Bradbury A, Shah PD, Knollman h, Jankowitz RC, Makhlin I, Clark AS, Chodosh LA, DeMichele A, Goodfellow KE. : P5-08-01: Pilot study of a patient-reported outcome (PRO) measurement strategy to determine impact of screening for minimal residual disease (MRD) in high-risk breast cancer survivors. San Antonio Breast Cancer Symposium 2022, San Antonio, TX. Dec 2022 Notes: "Poster Presentation"

Makhlin I, McAndrew NP, Wileyto EP, Clark AS, Holmes R, Bottalico LN, Mesaros C, Blair IA, Jeschke GR, Fox KR, Domchek SM, Matro JM, Bradbury AR, Feldman MD, Hexner EO, Bromberg JF, DeMichele A.: Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer. NPJ Breast Cancer 8(1): 122, Nov 11 2022.

Makhlin I, Korhonen KE, Martin ML, Gillman J, Schubert E, Pantel AR, Mankoff DA, Clark AS.: (18)F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer. Radiol Imaging Cancer 4(6), Nov 2022.

Igor Makhlin, Biniyam G. Demissei, Ralph D’Agostino, W. Greg Hundley, Anna Chen, Nathaniel Sean O’Connell, W.H. Wilson Tang, Bonnie Ky : Statins, Anthracyclines, and Left Ventricular Function: The Role of Oxidative and Nitrosative Stress Biomarkers in Understanding Cardiotoxicity Penn Stanford CVI Symposium 2022, Philadelphia, PA. Oct 2022 Notes: "Oral Presentation"

Makhlin I, DeMichele A.: Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer. Cell Rep Med 3: 100668, Jun 2022.

Dastgheyb SS, Kim K, Doucette A, Freedman G, Shah P, Makhlin I, Clark A, Taunk N.: Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients. Breast. 67: 26-29, Feb 2022.

Makhlin I, McAndrew N, Wileyto EP, Clark A, Holmes R, Bottalico LN, Jeschke GR, Fox KR, Domcheck SM,1 Matro JM, Bradbury AR, Shih N, Feldman MD, Hexner EO, Bromberg JF, DeMichele A. : P2-07-04 Analysis of host inflammatory and estrogen biomarkers in JAKEE: A phase II trial of the JAK inhibitor ruxolitinib in combination with exemestane for estrogen receptor-positive metastatic breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX. Dec 2021 Notes: "Oral Presentation"